← Back to Patent Explorer
US4650788A Expired / Lapsed US ⏱️ 0.0 years remaining

Novel peptides having an immunostimulating action, processes for their preparation and their use

Assignee: Hoechst AG
•
Filing: 1984-08-01
•
Granted: 1987-03-17
•
Expires: 2004-08-01
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to cyclopeptides of the formula I ##STR1## in which A denotes Lys, D-Lys, Arg or D-Arg, B denotes Lys, D-Lys, Arg or D-Arg, C denotes Asp, D-Asp, Glu or D-Glu, U denotes Val or D-Val and D denotes Tyr, D-Tyr, Trp, D-Trp, Phe or D-Phe, 1 to 4 of the radicals A, B, C, U and D being in the L-configuration and the remaining radicals being in the D-configuration, processes for their preparation, their use and peptidic precursors and processes for their preparation.

Inventors

  • 👤 Horst Kessler
  • 👤 Bernhard Kutscher
  • 👤 Rainer Obermeier
  • 👤 Hubert Mullner

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 06:58
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/66; C07K14/662; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/18; Y10S930/27

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 74 words
A cyclopeptide of the formula I ##STR10## in which A denotes Lys, D-Lys, Arg or D-Arg, B denotes Lys, D-Lys, Arg or D-Arg, C denotes Asp, D-Asp, Glu or D-Glu, U denotes Val or D-Val and D denotes Tyr, D-Tyr, Trp, D-Trp, Phe or D-Phe, 1 to 4 of the radicals A, B, C, U and D being in the L-configuration and the remainder being in the D-configuration, and a physiologically acceptable salt thereof.
Claim 2
Dependent Claim 74 words
A cyclopeptide of the formula I ##STR10## in which A denotes Lys, D-Lys, Arg or D-Arg, B denotes Lys, D-Lys, Arg or D-Arg, C denotes Asp, D-Asp, Glu or D-Glu, U denotes Val or D-Val and D denotes Tyr, D-Tyr, Trp, D-Trp, Phe or D-Phe, 1 to 4 of the radicals A, B, C, U and D being in the L-configuration and the remainder being in the D-configuration, and a physiologically acceptable salt thereof.
Claim 3
Dependent Claim 35 words
A cyclopeptide as claimed in claim 1, in which A denotes D-Lys or Arg, B denotes Lys, D-Lys or Arg, C denotes Asp or Glu, U denotes D-Val and D denotes Tyr, Trp or D-Phe.
Claim 4
Dependent Claim 11 words
A cyclopeptide as claimed in claim 1, wherein U denotes Val.
Claim 5
Dependent Claim 143 words
A peptide of the formula II ##STR11## in which W denotes Lys (R 1 ), D-Lys (R 1 ), Arg (R 2 ) or D-Arg (R 2 ), X denotes Lys (R 1 ), D-Lys (R 1 ), Arg (R 2 ) or D-Arg (R 2 ) and Y denotes Asp (R 3 ), D-Asp (R 3 ), Glu (R 3 ) or D-Glu (R 3 ) and U and D are as defined in claim 1, and in which R 1 represents a urethane-protective group, R 2 represents a protective group for the guanidino function and R 3 represents an ester-protective group, and (a) all five radicals a represent peptide bonds or (b) one of the radicals a denotes a C-terminal OH together with an N-terminal H (a=--OH+H--) of two aminoacid radicals and the remaining four radicals a each denote peptide bonds.
Claim 6
Dependent Claim 36 words
A pharmaceutical composition for treating deficiencies of immunity comprising an effective amount of a compound or a mixture of compounds as claimed in claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim 21 words
A method for influencing the maturing of lymphocytes which comprises treating said lymphocytes with a compound as claimed in claim 1.
Claim 8
Dependent Claim 26 words
A method of treating deficiencies of immunity by administering an effective amount of a compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim 25 words
A cyclopeptide as claimed in claim 1 in which A denotes Arg, B denotes Lys, C denotes Glu, U denotes D-Val and D denotes Tyr.

References Cited (Backward Citations)

DE2804566A1 Cited
GB1565032A Cited
EP0037246A2 Cited
US4298523A Cited
US4505853A Cited
US4547489A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-03-16 1990-09-15 1991-03-17 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-03-16 1994-09-15 1995-03-17 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-03-16 1998-09-15 1999-03-17 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag